MK-6837 is under clinical development by Merck and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success rate (PTSR) ...

Bempikibart (ADX-914) is under development for the treatment of atopic dermatitis and alopecia areata. It is administered through subcutaneous route and acts by targeting interleukin-7 receptor (IL-7R ...

Copper demand is expected to stay red-hot, according to Jorge Cantallopts, an executive director at the Center for Copper and ...

Bloomberg Green looks at how energy markets, consumer spending and diplomacy will shape the future of the planet this year.

Moderna/Merck partnership and its potential in personalised cancer therapies are good opportunities for long-term investors.

Pharmaceutical and biotech stocks may find it tough to outperform the market in the months ahead. That is the view of UBS ...

The World Bank in its latest report has highly appreciated the policies and the high tech moves of the Vietnam Government and ...

The cryptocurrency space is always in the headlines, and almost always for good reasons like a heavy rate of return. Elon ...

Signals from the incoming administration indicate a possible focus on policy pivots that they believe will result in a more ...

As 2024 ends, India’s AI sector has transitioned from its experimentation stage to strategic adoption, primarily driven by ...

The war between Russia and Ukraine has now entered its 1044th day since starting on February 24, 2022. In this relatively short time, drones have become a bona fide tour de force on the battlefield.

When Gloria Kopp got fed up with diet after diet that just didn't work, she took the advice of a friend who'd slimmed down with a commercial diet plan called the Medi-Weightloss Program.